Ehlers-Danlos Syndrome
Also known as: Cutis elastica, EDS, Disorder, Syndrome, Diseases
Methodology & AI Transparency ⓘ
Ehlers-Danlos Syndrome Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Ehlers-Danlos syndrome (EDS) is a group of inherited disorders that weaken connective tissues .
- 2 Real-world patient consensus: Clinical coding for Ehlers-Danlos Syndrome uses ICD-10 Q79.60 across Arthritis & Joints specialty care.
- 3 Typical cash cost range: Workup highlights for Ehlers-Danlos Syndrome (Q79.60): topical/targeted anti-inflammatory therapy [Ehlers-Danlos Syndrome Q79.60].
- 4 Top reported side effects / signs: Key Arthritis & Joints biomarkers for Ehlers-Danlos Syndrome (Q79.60): hs-CRP & Erythrocyte in Ehlers-Danlos Syndrome (Q79.60: Sedimentation Rate) & Weight-Bearing Joint Radiograph [Ehlers-Danlos Syndrome Q79.60] (Preserved joint-space width (Q79.60)).
Ask our AI Specialists anything about Ehlers-Danlos Syndrome
What Is Ehlers-Danlos Syndrome?
Ehlers-Danlos syndrome (EDS) is a group of inherited disorders that weaken connective tissues . Connective tissues are proteins that support skin, bones, blood vessels, and other organs. EDS usually affects your skin, joints and blood vessel walls. Symptoms include: Loose joints Fragile, small blood vessels Abnormal scar formation and wound healing Soft, velvety, stretchy skin that bruises easily There are several types of EDS. They can range from mild to life-threatening. About 1 in 5,000 people has EDS. There is no cure. Treatment involves managing symptoms, often with medicines and physical therapy.
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Ehlers-Danlos Syndrome (Q79.60, Arthritis & Joints) reflects monosodium urate or in Ehlers-Danlos Syndrome (Q79.60: calcium pyrophosphate crystal). Cross-referenced with NIH MeSH (Ehlers-Danlos Syndrome), longitudinal control is benchmarked via hs-CRP & Erythrocyte in Ehlers-Danlos Syndrome (Q79.60: Sedimentation Rate).
Common Symptoms & Clinical Signs
- • Fragile, small blood vessels
- • Abnormal scar formation and wound healing
- • Presentation of Ehlers-Danlos Syndrome (Q79.60): localized tendon or in Ehlers-Danlos Syndrome (Q79.60: bursa tenderness limiting)
- • Secondary Ehlers-Danlos Syndrome clinical sign: activity-related deep aching in Ehlers-Danlos Syndrome (Q79.60: joint pain in)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Ehlers-Danlos Syndrome Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | Q79.60 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Osteoarthritis, Gout & Joint Pain | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: hs-CRP & Erythrocyte in Ehlers-Danlos Syndrome (Q79.60: Sedimentation Rate) | hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (Q79.60) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Weight-Bearing Joint Radiograph [Ehlers-Danlos Syndrome Q79.60] | Preserved joint-space width (Q79.60) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Uric Acid in Ehlers-Danlos Syndrome (Q79.60: (Gout Target)) | < 6.0 mg/dL (< 5.0 mg/dL with tophi) (Q79.60) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Ehlers-Danlos Syndrome
Treatment selection for Ehlers-Danlos Syndrome depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Ehlers-Danlos Syndrome)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on A potential association of SLC2A9 variant rs7442295 with uric acid at baseline The mechanism of this iloperidone-induced increase in serum urate levels is likely due to decrease in clearance of urate through interaction with the SLC2A9 urate transporter protein. The pharmacogenomics journal • 2026-03-13 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41826282 ↗ |
| Can This Approach Help? Inside the Latest Research on Response to netakimab in radiographic axial spondyloarthritis patients with Subcutaneous netakimab is effective in patients with r-axSpA irrespective of baseline CRP and inflammation on SIJ MRI. Clinical and experimental rheumatology • 2023-03-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 36062743 ↗ |
| Can This Approach Help? Inside the Latest Research on Disease-Worsening Following Withdrawal of Etanercept or Methotrexate on Etanercept single-drug treatment showed benefit over methotrexate in maintaining PRO scores. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases • 2023-01-01 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 36459119 ↗ |
| Can This Approach Help? Inside the Latest Research on Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in In MTX-IR patients with RA, treatment with upadacitinib resulted in statistically significant and clinically meaningful improvements in PROs equivalent to or greater than with adalimumab. Rheumatology (Oxford, England) • 2021-12-01 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 33590829 ↗ |
Ehlers-Danlos Syndrome Patient Community & “People Like Me” Threads
Filter Ehlers-Danlos Syndrome community threads and patient logs by age, biological sex, dosage, and treatment duration.